http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Umut Kalyoncu ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Umut Kalyoncu ),( Abdulsamet Erden ),( Omer Karadag ),( Levent Kilic ),( Sule Apras Bilgen ),( Ali Akdogan ),( Ali Ihsan Ertenli ),( Sedat Kiraz ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Total hip replacement (THR) is a favorable treatment option for severe ankylosing spondylitis (AS). Objective of this study was to assess frequency of THR and hip involvement in a single center spondyloarthritis (SpA) biological dataset. Methods: HUR-BIO(Hacettepe University Rheumatology Biologic Registry) is a single center biological registry since 2005. HUR-BIO biological data set included demographic data, co-morbidities, smoking status, baseline and follow-up disease activity parameters (such as BASDAI, BASfi, CRP, ESR). Available digital radiographic imaging of pelvis were reassesed for hip inolvement and THR. Kaplan-Meier plots and log rank tests were used to assess TNfi drug survival. Results: 768 of 1290 (59. 5%) SpA patients had available pelvis radiography. 450 of 768 (58. 6%) patients were male and mean age was 41±11 years old, mean disease duration 8. 6±6. 9 years, mean TNfi duration was 32±29 months. Frequency of hip involvement in spondyloarthritis is in Table 1. Radiological hip involvement and severe hip involvement found in 125 (16. 3%) and 65 (8. 4%) patients, respectively. Patients with severe hip involvement was older age 47±11 vs 41±11, p<0. 001, more disease duration 15±9 vs 8±6 years, p<0. 001, more frequently male 47/65(72. 3%) vs 402/702 (57. 3), p=0. 018), more frequently advanced spinal disease 18/52 (34. 6%) vs 74/576 (12. 8%), p<0. 001. Baseline disease activity parameters were similar with and without severe hip involvement, however, last visit CRP (2. 56±2. 75 vs 1. 06±1. 97 mg/dl, p<0. 001), ESR (24±25 vs 13±14 mm/hour, p<0. 001) and BASfi (4. 7±2. 8 vs 2. 4±2. 1, p<0. 001) were higher in severe hip involvement. Disease duration was found independent risk factor for severe hip inolvement (OR 1. 13(95%CI 1. 09-1. 17). In all spondyloarthritis patients, TNfi drug survival was similar with and without severe hip involvement. Conclusions: Severe hip involvemet was demonstrated either AS or other spondyloarthritis. THR performed almost 5 percent of AS, PsA and enteropathtic arthritis. On the other hand, substantial of AS patients who need THR were not operated yet. The reasons of this delay may be responsible of patients` perspective or physicians. TNfi may not refi ect any major unfavotrable effect of THR.
-
( Omer Karadag ),( Abdulsamet Erden ),( Levent Kilic ),( Umut Kalyoncu ),( Ali Akdogan ),( Sule Apras Bilgen ),( Sedat Kiraz ),( Ihsan Ertenli ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Hydroxychloroquine(HQ) is widely used to treat for rheumatoid arthritis( RA) and connectice tissue disorders. Due to the potential of ocular toxicity,routine ophtalmological assessment(ROA) is essential for sight safety. Methods: In our outpatient clinic, patients with RA and connective tissue disorders such as systemic lupus erythematosus (SLE), sjogren syndorme (SS) and overlap were assessed consecutively for drug status of HQ by a standard questionnaire between December 2013 and January 2014. Patients who used HQ less than 1 year (13. 6%) were excluded from study. Ocular toxicity was taken from patients` reported. If ophthalmologist advised to cease HQ due to ocular toxicity,we accepted as ocular side effect. Patients with ocular toxicity were not reevaluated by an ophthalmologist. Cumulative HQ dosage and risk factors for ocular toxicity were assessed by using Mann-Whitney U test. Results: A total of 266 patients(90. 6% female) were enrolled. Mean age was 50±13. 5 years and median disease duration was 8 years(1-50). Median duration of HQ treatment was 6 years(1-28) and median dose was 400 mg/day. Of 46(17. 3%) patients were ceased HQ. The reasons of cease of HQ were ocular toxicity 22(47. 8%), patient non-adherence 9(19. 6%),dermatological side effect 3(6. 5%),others 12(26. 1%). 22 of all 266(%8. 3) patients developed ocular toxicity. Ocular toxicity was found more frequently in male 5/20(20%) vs 17/241(7%),p=0. 025). Median cumulative HQ dosage in patients with ocular toxicity was 864 gram (108-2160) in other words 12. 9 gr per kilogram( 1. 2-40). Older age (58±10 vs 50±13,p=0. 008),longer disease duration (14. 8±11. 5 vs 9. 2±7. 1 years,p=0. 013), and longer HQ duration (10±6. 3 vs 7. 1±5. 6 years,p=0. 023)were associated with ocular toxicity. Conclusions: Among regularly follow-up patients, ocular toxicity of HQ was not rare in a rheumatology outpatient clinic. Cumulative toxicity for ocular toxicity was 13 gram/kilogram;however, certain patients developed toxicity in 1 gram/kg/day. Although, important part of our patients was female, ocular toxicity was seen more frequently in male patients. Other risk factors such as longer disease duration,longer HQ usage and older age were also demonstrated in our patients.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
